Overview

Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
Phase:
Phase 3
Details
Lead Sponsor:
Alcon Research
Treatments:
Olopatadine Hydrochloride
Ophthalmic Solutions
Pharmaceutical Solutions